Welcome Guest user | Log in | Athens Login | Shibboleth Login | Register
Resources
Register
For Authors
For Librarians
For Advertisers
Services
Subscriptions/Pricing
Reprints
Advertising
Press Releases/News
Help
Downloads/Links
2008/9 Catalogue
Library Recommendation
 

Summary
June 2006, Vol. 7, No. 4, Pages 625-631 , DOI 10.2217/14622416.7.4.625
(doi:10.2217/14622416.7.4.625)

Special Report
Global pharmacogenetics: giving the genome to the masses
Sharon Marsh1,4, Derek J Van Booven1 & Howard L McLeod1,2,3,4
1Washington University School of Medicine, Department of Medicine, Room 1021 CSRB NT, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA .
2Washington University School of Medicine, Department of Molecular Biology & Pharmacology, St Louis, MO 63110, USA
3Washington University School of Medicine, Department of Genetics, St Louis, MO 63110, USA
4The Siteman Cancer Center, St Louis, MO 63110, USA
Author for correspondence



With pharmacogenetics comes the promise of individualized therapy selection for many common diseases where multiple treatment options are available. Recent advances including the Human Genome Project, the International HapMap project, advances in throughput and reduction in cost of genetic testing, and the inclusion of genotype-related dosing recommendations into package inserts all point to the integration of pharmacogenetics into clinical practice. However, many countries will not have access to pharmacogenetics resources in the near future. Generation of global genotype profiles will provide a useful, but not perfect resource for incorporating pharmacogenetics into national drug formularies in the form of prioritization or surveillance where individual genotype data would not be attainable. The PharmacoGenetics for Every Nation Initiative is a first step to making pharmacogenetics applicable on a global level.

Full Text PDF (152 KB) PDF Plus (234 KB)

Cited by

Oksana Makeeva, Vadim Stepanov, Valery Puzyrev, David B Goldstein, Iris Grossman. (2008) Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics 9:7, 847-868
Online publication date: 1-Jul-2008.
Summary | Full Text | PDF (620 KB) | PDF Plus (522 KB) 
Sharon Marsh. (2008) Pharmacogenetics: global clinical markers. Pharmacogenomics 9:4, 371-373
Online publication date: 1-Apr-2008.
Citation | Full Text | PDF (86 KB) | PDF Plus (128 KB) 
E Oliveira, S Marsh, DJ van Booven, A Amorim, MJ Prata, HL McLeod. (2007) Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 8:7, 703-712
Online publication date: 1-Jul-2007.
Summary | Full Text | PDF (234 KB) | PDF Plus (268 KB) 
 

Prev. Article | Next Article
View/Print PDF (152 KB)
View PDF Plus (234 KB)
Add to favorites
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Sharon Marsh
Derek J Van Booven
Howard L McLeod
Keywords:
FDA
genotype
global healthcare
PGENI
pharmacogenetics
pharmacogenomics
polymorphism
World Health Organization